Use of modified Fc fragments in immunotherapy
US12247076B2 · kind B2 · utility
0Cited by
76References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 6, 2016 |
| Grant date | Mar 11, 2025 |
| Priority date | — |
| Expiry date | Jul 22, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the use of antibody Fc fragments in the treatment of autoimmune and/or inflammatory diseases, said Fc fragments being isolated recombinant Fc fragments having a modified affinity for at least one of the Fc receptors (FcR), particularly an increased affinity to FcRn.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.